Literature DB >> 33787513

Does prior immunization with measles, mumps, and rubella vaccines contribute to the antibody response to COVID-19 antigens?

Danesh Hassani1, Mohammad Mehdi Amiri, Faezeh Maghsood, Vahid Salimi, Gholam Ali Kardar, Omid Barati, Seyed Mohammad Reza Hashemian, Mahmood Jeddi-Tehrani, Amir-Hassan Zarnani, Fazel Shokri.   

Abstract

BACKGROUND: Incidence and severity of SARS-CoV2 infection are significantly lower in children and teenagers proposing that certain vaccines, routinely administered to neonates and children may provide cross-protection against this emerging infection.
OBJECTIVE: To assess the cross-protection induced by prior measles, mumps and rubella (MMR) vaccinations against COVID-19.
METHODS: The antibody responses to MMR and tetanus vaccines were determined in 53 patients affected with SARS-CoV2 infection and 52 age-matched healthy subjects. Serum levels of antibodies specific for NP and RBD of SARS-CoV2 were also determined in both groups of subjects with ELISA.
RESULTS: Our results revealed significant differences in anti-NP (P<0.0001) and anti-RBD (P<0.0001) IgG levels between patients and healthy controls. While the levels of rubella- and mumps specific IgG were not different in the two groups of subjects, measles-specific IgG was significantly higher in patients (P<0.01). The serum titer of anti-tetanus antibody, however, was significantly lower in patients compared to healthy individuals (P<0.01).
CONCLUSION: Our findings suggest that measles vaccination triggers those B cells cross-reactive with SARS-CoV2 antigens leading to the production of increased levels of measles-specific antibody.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33787513     DOI: 10.22034/iji.2021.87990.1843

Source DB:  PubMed          Journal:  Iran J Immunol        ISSN: 1735-1383            Impact factor:   1.603


  4 in total

Review 1.  Measles, mumps and rubella vaccine and heterologous immunity: a way out of the COVID-19 crisis?

Authors:  Jahnavi Shrivastava; Manish Narang; Sunil Gomber
Journal:  Sudan J Paediatr       Date:  2022

2.  Does the rubella immunoglobulin G affect the severity of COVID- 19?  : Rubella immunoglobulin G and COVID- 19.

Authors:  Leyla Sahebi; Mohsen Hosseini; Alireza Abdollahi; Nahid Farrokhzad; Samrand Fattah Ghazi; Farzaneh Samaei Noroozi; Fereshteh Ghiasvand
Journal:  BMC Microbiol       Date:  2022-06-11       Impact factor: 4.465

3.  SARS-CoV-2 spike protein displays sequence similarities with paramyxovirus surface proteins; a bioinformatics study.

Authors:  Ehsan Ahmadi; Mohammad Reza Zabihi; Ramin Hosseinzadeh; Leila Mohamed Khosroshahi; Farshid Noorbakhsh
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

Review 4.  Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and vaccine design.

Authors:  Somayeh Ghotloo; Faezeh Maghsood; Forough Golsaz-Shirazi; Mohammad Mehdi Amiri; Christiane Moog; Fazel Shokri
Journal:  Rev Med Virol       Date:  2022-04-08       Impact factor: 11.043

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.